Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 7/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15836203 | 0.85 | LMNA (0.74) | LMNAKMT2AALDH1A1MEN1MAPT | |
| SCHEMBL1669579 | 0.85 | LMNA (0.74) | LMNATSHRKMT2AALDH1A1GAA | |
| SCHEMBL403618 | 0.85 | LMNA (0.74) | LMNATSHRKMT2AALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL9651756 | 0.84 | LMNA (0.72) | LMNATSHRKMT2AALDH1A1GAA | |
| SCHEMBL6529415 | 0.83 | LMNA (0.71) | LMNATSHRKMT2AALDH1A1TP53 | |
| SCHEMBL398167 | 0.83 | LMNA (0.71) | LMNATSHRKMT2AALDH1A1TP53 | |
| SCHEMBL8962352 | 0.82 | LMNA (0.70) | LMNAKMT2AALDH1A1L3MBTL1MEN1 | |
| SCHEMBL3917292 | 0.82 | LMNA (0.70) | LMNATSHRKMT2AALDH1A1TP53 | |
| SCHEMBL394260 | 0.81 | LMNA (0.69) | LMNATSHRKMT2AALDH1A1TP53 | |
| SCHEMBL1185864 | 0.81 | LMNA (0.69) | LMNATSHRKMT2AALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 285 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112409294-A | Benzothiazinone derivative, preparation method thereof and application of benzothiazinone derivative as antituberculosis drug | 苏州大学 | 2021-02-26 | — | — | CN | claimed |
| CN-112409293-A | Benzothiazinone compound, preparation method thereof and application of compound as antituberculosis drug | 苏州大学 | 2021-02-26 | — | — | CN | claimed |
| CN-111303075-A | Benzothiazinone derivative, preparation method thereof and application of benzothiazinone derivative as antituberculosis drug | 苏州大学 | 2020-06-19 | — | — | CN | claimed |
| CN-111269197-A | Benzothiazinone compound, preparation method thereof and application of compound as antituberculosis drug | 苏州大学 | 2020-06-12 | — | — | CN | claimed |
| US-20250188070-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2025-06-12 | — | — | US | disclosed |
| CN-112236428-B | Antiproliferative compounds and uses thereof | 默克专利股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| US-12195453-B2 | Antiproliferation compounds and uses thereof | MERCK PATENT GMBH (DE) | 2025-01-14 | — | — | US | disclosed |
| US-20240269293-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | OD THERAPEUTICS LIMITED (CN) | 2024-08-15 | — | — | US | disclosed |
| EP-4043460-B1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2024-06-05 | — | — | EP | disclosed |
| US-20240116872-A1 | PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| EP-4313154-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | OD Therapeutics Limited (HK) | 2024-02-07 | — | — | EP | disclosed |
| CN-117355337-A | Protein-macromolecule conjugates and methods of use thereof | 奥迪曼药业科技有限公司 | 2024-01-05 | — | — | CN | disclosed |
| WO-2002000633-A1 | QUINOLINYL AND BENZOTHIAZOLYL PPAR-GAMMA MODULATORS | TULARIK INC. (US) | 2002-01-03 | — | — | WO | disclosed |
| EP-0813533-A4 | SUBSTITUTED N-CYCLOALKYLMETHYL-1H-PYRAZOLO 3,4-b]QUINOLIN-4 AMINES AND COMPOSITIONS AND METHODS OF USE THEREOF | SANOFI WINTHROP INC (US) | 2000-01-19 | — | — | EP | disclosed |
| US-5942520-A | Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines | CELL PATHWAYS, INC. (US) | 1999-08-24 | — | — | US | disclosed |
| EP-0813533-A1 | SUBSTITUTED N-CYCLOALKYLMETHYL-1H-PYRAZOLO 3,4-b]QUINOLIN-4 AMINES AND COMPOSITIONS AND METHODS OF USE THEREOF | SANOFI WINTHROP, INC. (US) | 1997-12-29 | — | — | EP | disclosed |
| EP-0556673-B1 | Ortho-substituted benzoylguanidines, process for their preparation, their use as medicament or diagnostic agent, as well as medicaments containing them | HOECHST AG (DE) | 1997-09-17 | — | — | EP | disclosed |
| WO-1996028446-A1 | SUBSTITUTED N-CYCLOALKYLMETHYL-1H-PYRAZOLO[3,4-b]QUINOLIN-4 AMINES AND COMPOSITIONS AND METHODS OF USE THEREOF | SANOFI WINTHROP, INC. (US) | 1996-09-19 | — | — | WO | disclosed |
| US-5488055-A | ADMINISTERING GMP HOSPHODIESTERASE INHIBITORS FOR TREATMENT OF CONGESTIVE HEART FAILURE AND CARDIOVASCULAR DISORDERS | SANOFI WINTHROP INC. (US) | 1996-01-30 | — | — | US | disclosed |
| EP-0556673-A1 | Ortho-substituted benzoylguanidines for the treatment and prophylaxis of heart-rhythm disorders and ischaemically induced damage, as well as inhibition of cell proliferation | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240269293-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | CD44, MACROD1, MSN | LMNA 1994/4885TSHR 3309/4885KMT2A 2714/4885 |
| US-20240116872-A1 | PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING | SHH, GLI1, SMO | LMNA 3718/4885TSHR 453/4885KMT2A 1487/4885 |
| US-12195453-B2 | Antiproliferation compounds and uses thereof | MKI67, MCL1, CCNI | LMNA 1520/4885TSHR 3810/4885KMT2A 2819/4885 |
| US-20250188070-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MKI67, MCL1, CCNI | LMNA 1520/4885TSHR 3810/4885KMT2A 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.